The tetrapeptide AcetyCN-Ser-Asp-Lys-Pro (AcSDKP, Seraspenide; Ipsen-Biotech, Paris, France), an inhibitor of murine spleen colony-forming units reduces the number and the percentage in DNA synthesis of progenitors from human unfractionated bone marrow. To determine whether AcSDKP may directly affect the growth potential of purified progenitors even at the most primitive level, CD34+HLA-DRhigh and CD34++HLA-DR'OW cells were highly purified by cell sorting. Then, CD34+ subsets were stimulated in liquid culture with combinations of growth factors (GFs) and AcSDKP was added for 20 hours or 6 days and cells plated in methylcellulose. After a 20-hour incubation, we show that AcSDKP (at lo-'' mol/L) significantly inhibits the colony formation of both HE TETRAPEPTIDE Acetyl-N-Ser-Asp-Lys-Pro T (AcSDKP), isolated from fetal calf marrow1,* and now chemically syntheti~ed,~ inhibits the entry into DNA synthesis of murine pluripotent stem cells (spleen colony-forming units [CFU-SI) after cytosine arabinoside treatment. Moreover, its administration increases the survival of mice to high doses of ~hemotherapy.~.~ Using in vitro clonogenic assays, we previously showed that AcSDKP inhibited the growth of human granulo-macrophagic (CFU-GM) and erythroid (BFU-E) progenitors from normal bone marrow (BM) and decreased their percentage in DNA synthesis,' whereas no effect on leukemic cells was These results suggest that AcSDKP might be useful in protecting normal hematopoietic progenitors against cytotoxic therapy during leukemias.
T (AcSDKP), isolated from fetal calf marrow1,* and now chemically syntheti~ed,~ inhibits the entry into DNA synthesis of murine pluripotent stem cells (spleen colony-forming units [CFU-SI) after cytosine arabinoside treatment. Moreover, its administration increases the survival of mice to high doses of ~hemotherapy.~.~ Using in vitro clonogenic assays, we previously showed that AcSDKP inhibited the growth of human granulo-macrophagic (CFU-GM) and erythroid (BFU-E) progenitors from normal bone marrow (BM) and decreased their percentage in DNA synthesis,' whereas no effect on leukemic cells was These results suggest that AcSDKP might be useful in protecting normal hematopoietic progenitors against cytotoxic therapy during leukemias.
However, these studies were performed on unfractionated BM and cord b l~o d~,~, '~ and did not allow the investigators to conclude at which level of the hematopoietic stem cell hierarchy AcSDKP may act. The experiments presented here were designed to determine whether or not AcSDKP could directly affect the growth potential of purified human progenitors even at the most primitive level. To this end, we highly purified CD34+ HLA-DRhi" and CD34++HLA-DRIoW cell fractions by flow cytometry. The latter fraction is enriched in more primitive cells such as long-term culture initiating cells (LTC-IC)," which may represent cells capable of reconstituting hematopoiesis in vivo,'* and high proliferative potential cells (HPP-CFC).I3 These two CD34+ subpopulations were stimulated by combinations of growth factors (GFs), with or without AcSDKP and tested both in clonogenic and proliferative assays. The results showed that AcSDKP reduces the clonogenicity and the cell proliferation of both CD34+ cell subsets. Using HPP-CFCL3 and LTC-IC assays," we showed that the most primitive cells are responsive to the inhibitory effect of AcSDKP within the same range as the progenitors. Further experiments using a limiting dilution assay indicate that AcSDKP acts directly on CD34+ cells at nanomolar concentration and that its inhibitory effect is reversible. CD34+ subsets. Moreover, when added daily for 6 days, AcSDKP: (1) reduces the proliferation of both CD34+ cell fractions stimulated by 3 or 7 GFs, and (2) decreases the number of progenitors generated from the CD34+HLA-DRhiQh and CD34++HLA-DR'OW cell fractions. Furthermore, we show for the first time, using both high proliferative potential cell and long-term culture initiating cell assays, that AcSDKP inhibits the most primitive cells contained in the CD34++HLA-DR'OW subpopulation. Finally, by using limiting dilution assays we demonstrated that AcSDKP acts directly at a single cell level and that its inhibitory effect is reversible and dose dependent. 0 1993 by The American Society of Hematology.
MATERIALS AND M€THODS

Cells
Human BM samples were obtained after informed consent either from fragments of femurs removed during orthopedic surgery from patients free of hematologic diseases or by iliac crest aspiration from normal donors for allogeneic transplantation. BM was first centrifuged at 200g for 10 minutes to remove the fat, and mononuclear cells (BMMNC) were separated on Ficoll-Hypaque gradient (Seromed, Berlin, Germany) (density 1.077 g/mL).
Reagents
Peptide. The synthetic tetrapeptide AcSDKP was kindly provided by Ipsen-Biotech (Paris, France). The lyophilized material was kept at 4°C and diluted in Iscove's modified Dulbecco's medium (IMDM) just before use at concentrations ranging from to mol&. Growth factors. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; specific activity [SA]: 5 X lo7 U/mg) and rh interleukin-3 (rhIL-3, SA: 9.6 X IO6 U/mg) were a generous gift from Genetics Institute (Cambridge, MA), rh erythropoietin (rhEpo) was provided by Boehringer (Paris, France); rhIL-p (SA: 5 X 10' U/mg) and rh tumor necrosis factor CJ (rhTNFa, SA: 2
3308
BONNET ET AL X IO' U/mg) were purchased from Genzyme (Boston, MA); rhIL-6 (SA: IO6 U/&, was a generous gift from Dr L. Aarden (Red Cross Hospital, Amsterdam, The Netherlands); rhG-CSF factor was provided by Rhbne-Poulenc (Paris, France) and rh stem cell factor (rhSCF) was a gift from Dr K. Zsebo (Amgen, Thousand Oaks, CA).
Monoclonal Antibodies (MoAbs)
Phycoerythrin-conjugated HLA-DR (IgG2a) (PE-HLA-DR) MoAb was purchased from Becton Dickinson (San Jose, CA). Isothiocyanate of fluoresceine-conjugated CD34 (CD34-FITC 8G 12) was a gift from Dr P. Lansdorp (Terry Fox Laboratory, Vancouver, Canada). Mouse IgG2a-PE and IgGI-FITC used as controls were purchased from Coultronics (Margency, France).
Staining Procedure and Cell Sorting
BMMNC were directly stained with CD34 and HLA-DR MoAbs as follows: cells were incubated with PE-HLA-DR and 8G12-FITC (0.5 pg/106 cells) for 20 minutes at 4"C, washed three times, and then kept on ice until use. Unstained cells and cells labeled with isotype-matched mouse IgG-PE and IgG-FITC of irrelevant specificity were used as negative controls. All staining and washes were performed in phosphate-buffered saline (PBS) containing 2% fetal calfserum (FCS). Fluorescence analysis was performed using a twolaser cytometer EPICS Elite (Coultronics, Margency, France). Fluorescence attributable to FITC-and PE-labeled antibodies was determined using excitation by argon laser operating at 488 nm. Forward-and side-scatter measurements were made with linear amplification and all fluorescence measurements were made with logarithmic amplification. Data were acquired using a software Elite and the proportion of positive cells was estimated by determining the channel number where the negative control and the test sample curves crossed each other. Cells were analyzed and sorted on the basis of their light scatter properties and fluorescence intensity as published elsewhere." Briefly, as shown in a representative experiment (Fig I) , a blast gate (A) was drawn according to a low to moderate forward scatter (FS) and to a very low side scatter (SS). Within this gate, CD34++ HLA-DR'" (gates EG) and CD34+ HLADRh@ (gates DF) cells were obtained and sorted at 2,000 cells per second and collected in PBS containing 50% FCS. The cell viability evaluated by trypan blue exclusion was always higher than 95%. The purity, which attained more than 9676, was assessed by analyzing an aliquot of sorted cells immediately after sorting. Cells were washed to remove FCS and the pellet was resuspended in IMDM-5% FCS.
Liquid Culture and Proliferation Assay
For cell proliferation, sorted cells were seeded in 96-well roundbottomed tissue culture plates (Falcon, 3077; Becton Dickinson) at 4 X IO3 cells/l00 pL in IMDM-5% FCS with the combination of either three GFs: IL-3 (100 U/mL) + TNFa (500 U/mL) + SCF (100 ng/mL), or seven GFs: IL-3 (100 U/mL) + IL-6 (100 U/mL) + IL-10 (100 U/mL) + GM-CSF (200 U/mL) + G-CSF (50 ng/mL) + Epo (3 U/mL) + SCF (100 ng/mL) for 6 days. Under these conditions, cells were incubated either without or with AcSDKP ( to mol/L) added daily during 6 days at 37°C in 5% CO,. Then, cells were pulsed with 'H-thymidine (CEA, Saclay France; specific activity: 25 Ci/mmol, 1 pCi/mL) for an additional 16 hours, harvested (PHD Cell Harvester, Cambridge Technology) onto glass fiber filters that were placed in a vial with I mL complete liquid scintillation fluid (Ready Safe; Beckman, Gagny, France) and counted (Liquid Scintillation Counter, 1209 Rackbeta; LKB Wallac, Turku, Finland). Because there is a direct correlation between ;he increase of thymidine incorporation and the absolute number of cells, we estimated the proliferative rate by the index of thymidine incorporation. Background count in the absence of cells was constantly less than 50 counts per minute (cpm).
Clonogenic Assay
After 20 hours or 6 days of liquid culture in the presence of seven GFs and with or without AcSDKP (see above), cells were plated at 1,500 cells/mL in semisolid medium containing 0.8% methylcellulose, 30% FCS, 1% bovine serum albumin (BSA), 100 pmol/L 2-mercaptoethanol, 2 mmol/L glutamine, 3 U/mL rhEpo, 100 U/mL rhIL-3, 200 U/mL rhGM-CSF, and 100 ng/mL rhSCF. Triplicate cultures were incubated in a humidified atmosphere containing 5% CO, in air at 37°C. Colonies were scored under an inverted microscope for BFU-E and CFU-GM at I8 days ofculture, whereas HPP-CFC-derived colonies were enumerated on day 28 according to previously established criteria. l3
LTC-IC Assay
LTC-IC assays were performed as described." Briefly, LTCs were established in 96-well flat-bottomed tissue culture plates (Falcon, 3072; Becton Dickinson) with 150 pL of LTC medium per well, and were seeded with 1,000 CD34++HLA-DRi" sorted cells per well. Cell suspension was seeded in IO separate wells with or without a daily addition of AcSDKP (IO-'' mol/L) for 5 weeks. All LTCs were initiated by seeding the test cells on semiconfluent irradiated (1 5 C y of 250 kilovolt [peak] x-rays) human marrow feeder layers subcultured from pre-established 2-to 6-week-old LTC adherent layer." Half-medium changes were performed weekly, and after 5 weeks the nonadherent cells and the adherent cells obtained after tryp~inizationl~ were washed and plated in triplicate in methylcellulose assay (see above) to determine the total clonogenic content of each LTC. Division by 4 of the total clonogenic progenitor content at 5-week time point gives the number of LTC-ICs present in the initial population assayed."
Limiting Dilution Assay
Limiting dilution assays were performed as described.15 Briefly, 0.3 to 40.5 cells per round-bottomed well were incubated in 100 pL IMDM containing 5% FCS, 0.5% wt/vol BSA, the combination of seven GFs as indicated above, and with or without AcSDKP added daily at various concentrations. One hundred eighty to 420 wells were seeded per concentration and per group. After 7 days of culture, positive wells were scored using an inverted microscope. For calculation of the clone frequency, data were plotted as the log of the fraction of nonresponding cells versus the number of cells plated per well. In some experiments, at selected cell concentrations, the number of cells per clone was determined. The average clone size was calculated as the ratio oftotal cell number numerated in 120 wells seeded at 1.5 cells per well divided by the number of positive wells observed. Calculations were performed on triplicates.
Statist ical Analysis
Results are given as the mean +-SEM. For each case, the mean number ofcounts per minute or progenitors obtained without (control) or with various doses of AcSDKP were globally tested by analysis of variance. When overall significance was reached, the effect at a given dose was tested against the control by Dunett's test. 16 For limiting dilution assays, linear regression was applied to the data to calculate the best slope." Conformance of the data to linearity was tested by using an F test: P < .05 indicating single-hit curves, thus demonstrating activity on a single cell. Therefore, we compared the slope of the curves (control v AcSDKP) by Student's 1- 
RESULTS
AcSDKP Inhibits the Colony Formation From CD34' Cell Siibpopulations
To test whether or not AcSDKP may affect the formation of colonies from CD34' cells, both CD34' HLA-DRhia and HLA-DR'O" cell fractions were incubated at IO4 cells/well with AcSDKP during 20 hours and then plated in methycellulose assay. As shown in Table 1 , AcSDKP decreased the number of BFU-E and CFU-GM present in the CD34'HLA-DRhigh fraction by 29% f 3% and 30% f 5%, respectively, and by 27% f 2% and 42% f 2%, respectively, in the CD34" HLA-DR'O" fraction. This inhibition was obtained with AcSDKP at to mol/L, higher or lower concentrations being ineffective (data not shown).
AcSDKP Decreases the Proliferative Rate of CD34' Cells Stimulated in Liquid Ciilture by Various Combinations of GFs
To test the effect of AcSDKP on the proliferation of CD34' subsets, cells were induced to proliferate by two com- binations of GFs. In a first set of experiments, rhIL-3 + TNFa + SCF (three GFs) were used. Figure 2A shows that AcSDKP reduced the thymidine incorporation of HLADRhia and HLA-DR'"" CD34' cell fractions by 37% f 13% and 58% f 17%. respectively. Because we have shown in a preliminary report'' that the proliferation of CD34+ cell fractions can be further increased using a combination of seven GFs, ie, rhIL-3 + IL-IP + IL-6 + G-CSF + GM-CSF + SCF + Epo, a second set of experiments was performed.
Under this optimal condition of stimulation, AcSDKP reduced the thymidine incorporation of HLA-DRhia and HLA-DR'O" CD34' cell fractions by 48% ? 7% and 65% f 5%, respectively (Fig 2B) . Interestingly, this inhibitory effect was only observed at concentrations ranging from lo-' to mol/L, whereas higher (IO-' mol/L) and lower con- For centrations ( mol/L) were ineffective (Fig 3) . These data indicate that, whatever the combination of GFs used, AcSDKP induces a significant decrease of the proliferation of both CD34+ subsets.
AcSDKP Reduces the Number of Progenitors Generated
From CD34+ Subpopulations After 6 Days of Liquid Culture With Seven GFs
We previously reported that liquid culture of CD34+HLA-DRhiph and CD34++HLA-DR'OW cell fractions in the presence of seven GFs for 6 days resulted in the enhancement of the colony formation from these human hematopoietic stem cells (HSC).I8 To determine whether or not AcSDKP may decrease the colony formation under these conditions, both CD34+ cell fractions were incubated with or without a daily addition of AcSDKP at lo-'' mol/L for 6 days and then plated in methylcellulose (see Materials and Methods). Table 2 shows that AcSDKP induces a significant decrease of the total number of progenitors (CFU-GM + BFU-E) ranging from 49% to 7 1% and from 49% to 94% in the CD34+HLA-DRhiBh and CD34++HLA-DR'OW cell subsets, respectively.
AcSDKP Reduces the Number of Both HPP-CFCs and LTC-ICs Present in the CD34++HL4-DRioW Cell Fraction
The CD34++ HLA-DR'O" cell fraction is enriched for HPP-CFCs and LTC-ICs cells that represent the most primitive hematopoietic progenitors cells that can be presently assayed in vitro in human marrow. Therefore, using HPP-CFC and LTC-IC assays, we studied whether AcSDKP acts on very primitive progenitors. After addition of AcSDKP to CD34++ HLA-DR'O" cells for either 20 hours or 6 days, the number of HPP-CFC was significantly reduced (Table 3) . CD34+'HLA-DR'Ow cells were also plated in LTC without or with a daily addition of AcSDKP, and LTC-ICs were evaluated after 5 weeks of peptide treatment. Table 4 shows that under this condition, AcSDKP significantly decreased the number of LTC-ICs.
Direct and Reversible Inhibitory EApct of AcSDKP on Individual CD34' Cells
Although the present data indicate that AcSDKP acts on CD34' cells, including the most primitive, whether or not AcSDKP modified the response of CD34+ to GFs directly or through an indirect mechanism involving accessory cells remained questionable. To answer this question, the effect of AcSDKP was evaluated on individual CD34+ cells using limiting dilution assays. Because both CD34+ subsets responded in the same way to the tetrapeptide, the limiting dilution studies were performed on purified CD34+ cells without taking into account the HLA-DR expression. Therefore, CD34+ cells were seeded at various concentrations into microtitration plates in the presence of seven GFs with or without a daily addition of AcSDKP for 7 days. The number of growing clones was determined after 7 days of culture. As shown in Fig 4, AcSDKP at lo-'' mol/L decreased the frequency of GF-responding CD34+ BM cells and led to the generation of 40% to 60% less clones than in control (AcSDKP untreated cells). When AcSDKP was used at higher concentration ( mol/L), no change in the clone frequency was observed. Interestingly, we obtained similar results with CD34+ from cord blood (data not shown). Thus, the fact that the inhibitory effect ofAcSDKP is seen at very low cell concentration (0.3 cells per well) and the linear slope of the frequency analysis curves show that AcSDKP acts directly on CD34' cells. In addition, these data confirmed the bell-shaped dose-response curve previously described.
To test whether the inhibitory effect of AcSDKP was reversible or not, AcSDKP was added at IO-'' mol/L during 3 days only and the clonal frequency was estimated at day 3 After 20 hours or 6 days of liquid culture in seven GFs with or without a daily addition of AcSDKP (lo-'' mol/L), cells were counted in trypan blue and plated at 1,500 cells/mL in methylcellulose. The total number of progenitors/well was tabulated as indicated in Table 2 Cultures performed in the presence of AcSDKP and GFs yielded a smaller number of large clones (>500 cells) and a higher number of small clones (<50 cells) than those performed with seven GFs alone. This is illustrated by a shift of the clone size distribution toward the smaller clones (Fig 5) . Although the difference is not statistically significant (. 1 < P > -051, the fact that We obtained a smaller average clone size in AcSDKP-treated cells: 250 f 66 cells per clone (untreated Thus, the overall experiments performed at a single cell level clearly show that AcSDKP acts directly at nanomolar concentration and in a reversible manner on CD34+ cells.
DISCUSSION
and 4 days later. Table 5 represents the number of positive wells out of 420 seeded at 0.3 cells/well and shows that the diminution of the clone frequency observed at day 3 was no We previously showed that AcSDKP is a potent negative regulator of human hematopoietic cell growth in vitro, inhibiting the entry into DNA synthesis of progenitors present in unfractionated BM and cord b l 0 0 d .~~'~ In this report, we longer seen at day 7. These data show the reversible action of AcSDKP on CD34+ cells.
We further questioned whether or not AcSDKP can modify the clone size. For this purpose, in two separate experi- studied the effect of AcSDKP on purified CD34+ cell subsets both in liquid and semisolid culture systems. Firstly, we showed that an incubation of CD34+HLA-DRhiBh or HLA-DR'OW cells with AcSDKP for 20 hours induced a significant reduction of the number of clonogenic progenitors (Table I) , confirming the inhibitory effect ofthe peptide previously reported on unfractionated mononuclear cells. ' Secondly, we investigated the effect of AcSDKP on both the proliferation of CD34' cells in liquid culture and on the generation of colonies from CD34+ subsets in response to recombinant growth factors. Therefore, we chose two different combinations of GFs, both including stem cell factor that appears to be essential to maintain the viability of immature precursors and to render them competent to display a high proliferative potential in the presence of other hematopoietic growth The first combination encompassed interleukin-3 (IL-3), SCF, and also TNFa, which has been reported to strongly potentiate the IL-3 and/or GM-CSF-induced growth of CD34+ ~e1ls.l~ Secondly, we used a combination of seven GFs that was shown in our laboratory" to further enhance the proliferation of CD34+ cell subsets as well as the colony generation. With either GF combination, the daily addition of AcSDKP (lo-'' mol/L) For personal use only. on October 23, 2017. by guest www.bloodjournal.org From induced a significant decrease of the proliferation of the two CD34+ cell fractions (Fig 2) . It should be pointed out that the more important the recruitment of CD34+ cells into the cell cycle by growth factors (7 GFs > 3 GFs) is, the higher the inhibitory action of the tetrapeptide (Fig 2) .
Interestingly, the inhibition of the proliferation was also observed on the more immature compartment, ie, the CD34+'HLA-DR1O" cells, which contains LTC-IC" and exhibits a very high growth potential in response to GF combinations. These findings suggest that AcSDKP may act at a very primitive level of the HSC hierarchy. Indeed, our data using HPP-CFC and LTC-IC assays show for the first time that AcSDKP acts on the most primitive cells. These findings are in agreement with Cashman et a]," who demonstrated that in human LTC, AcSDKP reversibly blocks the entry into S phase of high proliferative potential erythroid and granulocytic progenitors present in the adherent layer.
The inhibitory effect of AcSDKP appeared to be dose dependent, being observed at low concentrations and disappearing at higher concentrations. Such a bell-shaped curve, which has previously been reported on unfractionated BM, can suggest that the peptide might also have an indirect effect through accessory cells, as suggested by Cashman et a]," and that high concentrations of AcSDKP induce accessory cells to release factor(s) able to counterbalance its suppressive effect. However, our data obtained using limiting dilution assays clearly show the direct effect of AcSDKP on single CD34+ cell. Another possibility is that AcSDKP at high concentrations induced a down modulation of a possible receptor or postreceptor, as reported for TNFn." The identification and the characterization of a putative receptor or postreceptor would certainly be helpful to explain this phenomenon observed even at a single cell level.
Furthermore, we showed that the inhibitory effect of AcSDKP is reversible, confirming previous observations in long-term BM culturesz3 (Table 5 ). This property excludes any enhancing effect of the tetrapeptide on apoptosis by contrast to transforming growth factor PI (TGF@1).24
The present data allow us to conclude that AcSDKP inhibits the colony formation of CD34+ cells and reduces both the proliferation and the colony generation from CD34+ subsets stimulated by GFs. This effect is direct, reversible, and obtained at nanomolar concentrations.
Although the mechanism of the inhibition observed in our present investigation is not yet known, one might speculate that AcSDKP downregulates G F receptors as reported for other f a~t o r s ;~-~~ and/or blocks intracellular signaling pathways. Because we showed previously that AcSDKP inhibits the entry of cells into DNA ~ynthesis,~ suggesting that it may act during the GI-S transition, it could be interesting to study the effect of AcSDKP on the expression of cell-cycle regulators like nuclear proto-oncogenes (c-myc, c-fos, c-jun) as well as cyclins (A, D, E), cdk2 kinase, and suppressor genes (Rb, ~5 3 ) . " "~ Such studies are now in progress.
However, it is likely that AcSDKP plays a role in the negative control of normal hematopoiesis as TGFP 1, the pentapeptide pGlu-Glu-Asp-Cys-Lys and MIP I In addition, the property of AcSDKP to reversibly arrest the proliferation of normal CD34+ cells even at a very primitive level and its absence of action already reported on leukemic cells' are important in view of its application as a BM protector during chemotherapy. In this respect, the first results of a clinical trial are en~ouraging.~'
